Real-world dose adjustments occurred in patients with primary immunodeficiency who switched from intravenous immunoglobulin to subcutaneous immunoglobulin 20%, with resulting implications for payers, patients, and plasma collection and supply.
Michelle Luo, PhD
Advertisement
Articles by Michelle Luo, PhD
Advertisement
Latest Updated Articles
Real-World Immunoglobulin Dose Adjustments and Impact on Utilization and CostsPublished: April 18th 2016 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Announces Recall 580,000 Bottles of Prazosin Over Potential Carcinogenic Impurity
2
Regular Melatonin Supplementation May Hide Hidden Heart Complications
3
Early Detection of Type 1 Diabetes: The Power of Screening and Preparation
4
COVID-19 During Pregnancy Raises Neurodevelopmental Risks in Children
5
